Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight against prostate cancer. Like other gene expression-based tests, Prolaris for many years has been included in NCCN guidelines with category 2A level of evidence, meaning its inclusion has support from at least 85% of members on the NCCN prostate panel. “The updated NCCN Prostate Cancer Guidelines continue to solidify Prolaris’ market position,” said Paul J. Diaz, President and CEO, Myriad Genetics. “While there have been certain mischaracterizations regarding the updated guidelines leading to confusion, extensive published evidence shows that Prolaris is a clinically recognized and effective tool in managing patients with prostate cancer. We are confident that our highly engaged clinicians will continue to see the guidelines as an additional reason to incorporate Prolaris in treatment decisions.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Leerink downgrades Myriad Genetics on reimbursement, competitive headwinds
- Myriad Genetics downgraded to Market Perform from Outperform at Leerink
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
- Myriad announces Prequel Prenatal Screening can be performed at 8 weeks
- Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley